Altimmune, Inc. (ALT) fair value analysis
Nasdaq · Updated 2026-10-19
ALT price how computed
Valuation status
No fair-value estimate yetALT has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for ALT yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $2.20
- Sector
- Healthcare
- 12-month range
- $2.20–$6.18
- Market cap
- $428M
- From 52-week high
- -64.4%
- Shares outstanding
- 195M
- Rank in Healthcare by quality score
- #217 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Altimmune, Inc. is a clinical-stage biopharmaceutical company that focuses on developing immunotherapies and vaccines for diseases including cancer and infectious diseases. The company is headquartered in the United States and conducts its research and development operations domestically.
ALT currently ranks #217 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $428M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $31K
- Net margin
- -296000.0%
- EPS (TTM)
- $-0.78
- Debt / equity
- 0.08
- Revenue growth (3-yr avg)
- -33.3%
- Shares outstanding
- 195M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 16 · oversold
- 50-day average
- $3.00
- 200-day average
- $3.37
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Dividends how computed
- Dividend
- None in the last 12 months (last ex-date 2017-02-06)
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+20.0%)
2026-03 ▲ beat (+28.0%)
2025-12 ▼ miss (-8.4%)
2025-09 ▲ beat (+22.2%)
2025-06 ▲ beat (+15.6%)
2025-03 ▲ beat (+23.5%)
2024-12 ▲ beat (+1.5%)
2024-09 ▲ beat (+11.1%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 9 buy · 1 hold · 0 sell (10 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $17.1
- Target vs last price
- +677.3%
What our data shows for ALT
- Shares are trading in the lower third of their 12-month price range of $2.20–$6.18.
- The 14-day relative strength index sits at an oversold 16.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- ALT's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the ALT conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for ALT in the Healthcare sector shifted this week as the Relative Strength Index moved from neutral territory into oversold conditions. The stock's current valuation verdict remains awaiting full valuation. This technical development reflects selling pressure in the stock over the recent period.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is ALT stock undervalued?
TickrTrends has no fair-value estimate for ALT yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is ALT's TickrTrends verdict?
ALT is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does ALT compare to other Healthcare stocks?
ALT ranks #217 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is ALT overbought or oversold?
ALT's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
Does ALT pay a dividend?
ALT has paid no dividend in the last twelve months; its last ex-dividend date on file was 2017-02-06.
When does ALT report earnings next?
ALT's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does ALT usually beat earnings estimates?
Over its last 8 reported quarters ALT beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ALT?
Of 10 analysts covering ALT, 9 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $17.1 (+677.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.